News Details - Moderna
WEBMar 26, 2024 · The NEXTCove clinical trial is a randomized, observer-blind, active-controlled study of approximately 11,400 individuals aged 12 years and older in the United States, United Kingdom and Canada. mRNA-1283 was found to have a similar safety profile to Moderna's approved COVID-19 vaccines.
News Details - Moderna
WEBMar 27, 2024 · Announces positive clinical trial data from three new vaccines against viruses that cause significant burden (Epstein-Barr virus, Varicella-Zoster virus, norovirus) and advances programs toward Phase 3 development. Anticipates U.S. launch of vaccine against RSV following FDA approval and ACIP recommendation in 2024.
News Details - Moderna
WEBSep 11, 2023 · Moderna's updated COVID-19 vaccine contains spike proteins for the XBB.1.5 sublineage of SARS-CoV-2 to help prevent COVID-19 in individuals 6 months of age and older. With the U.S. FDA's decision, Moderna will begin shipping doses to vaccination sites across the U.S., with updated vaccines expected to be available in the …
Moderna says its RSV shot is 50% effective across a second season
WEBNEW YORK, June 26 (Reuters) - Moderna Inc (MRNA.O) respiratory syncytial virus (RSV) shot mRESVIA showed 50% efficacy in preventing RSV after 18 months, the drugmaker said on Wednesday.
FDA approves COVID shots from Moderna and Pfizer : Shots - Health News ...
WEBSep 11, 2023 · Another round of COVID-19 vaccines is on the way. The Food and Drug Administration approved vaccines from Pfizer and Moderna that target an omicron subvariant called XBB.1.5.
Moderna vaccine safe and effective, say US experts - BBC
WEBDec 15, 2020 · Moderna's vaccine is safe and 94% effective, regulators say, clearing the way for US emergency authorisation. The analysis by the Food and Drug Administration's (FDA) means it could become the...
News Details - Moderna
WEBOct 24, 2023 · mRNA-1083 is Moderna's first respiratory combination vaccine candidate to enter a Phase 3 trial. Phase 3 initiation follows data from a Phase 1/2 trial where mRNA-1083 showed strong immunogenicity against influenza and COVID-19, with an acceptable reactogenicity and safety profile, compared to licensed standalone vaccines.
Moderna Inc - The New York Times
WEBNews about Moderna Inc. Commentary and archival information about Moderna Inc from The New York Times.
FDA Approves and Authorizes Updated mRNA COVID-19 Vaccines …
WEBAugust 22, 2024. Today, the U.S. Food and Drug Administration approved and granted emergency use authorization (EUA) for updated mRNA COVID-19 vaccines (2024-2025 formula) to include a monovalent...
Moderna jumps as vaccine shows benefit in head and neck cancer …
WEBApril 9 (Reuters) - Moderna (MRNA.O) shares rose 8% to a three-month high on Tuesday after the company's individualized cancer vaccine developed with Merck (MRK.N) showed positive response in an...
Skip to content